跳转至内容
Merck
CN

SML2077

Aliskiren hemifumarate

≥95% (HPLC), Renin inhibitor, powder

别名:

(2S,4S,5S,7S)-N-(2-Carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamide hemifumarate, CGP-60536, CGP60536B, Rasilez, SPP-100

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C30H53N3O6 · 0.5 C4H4O4
化学文摘社编号:
173334-58-2
分子量:
609.79
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
MFCD27756642

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Aliskiren hemifumarate, ≥95% (HPLC)

InChI

1S/2C30H53N3O6.C4H4O4/c2*1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36;5-3(6)1-2-4(7)8/h2*10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35);1-2H,(H,5,6)(H,7,8)/b;;2-1+/t2*22-,23-,24-,25-;/m00./s1

SMILES string

CC(C)[C@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(NCC(C)(C)C(N)=O)=O)CC1=CC=C(OC)C(OCCCOC)=C1.OC(/C=C/C(O)=O)=O

InChI key

KLRSDBSKUSSCGU-KRQUFFFQSA-N

assay

≥95% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

相关类别

Biochem/physiol Actions

Aliskiren hemifumarate (ALS) has been used to treat hypertension, alone or with other antihypertensive medications. It is suitable for oral administration. ALS regulates baseline systolic and diastolic blood pressure by blocking the catalytic activity of renin system at its rate-limiting step.
Aliskiren is a potent nonpeptide direct renin inhibitor with an IC50 value of 0.6 nM. It has antihypertensive activity, decreasing plasma renin activity and inhibiting the conversion of angiotensinogen to Angiotensin I by binding to the S3 sub-pocket of renin.
Direct renin inhibitor; anti-hypertensive

存储类别

11 - Combustible Solids

wgk

WGK 3

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000350493
0000350493
0000132386
0000132386
0000132385

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Jeanette M Wood et al.
Biochemical and biophysical research communications, 308(4), 698-705 (2003-08-21)
Hypertension is a major risk factor for cardiovascular diseases such as stroke, myocardial infarction, and heart failure, the leading causes of death in the Western world. Inhibitors of the renin-angiotensin system (RAS) have proven to be successful treatments for hypertension.
Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor.
Ali A K
Therapeutics and Clinical Risk Management, 7, 337-337 (2011)
Simultaneous determination of aliskiren hemifumarate, amlodipine besylate, and hydrochlorothiazide in their triple mixture dosage form by capillary zone electrophoresis.
Salim M M, et al.
Journal of Separation Science, 37(9-10), 1206-1213 (2014)
Nikolaos-Dimitrios Pantzaris et al.
Journal of clinical medicine, 6(6) (2017-06-10)
The renin-angiotensin-aldosterone system (RAAS) plays a key role in the pathophysiology of arterial hypertension as well as in more complex mechanisms of cardiovascular and renal diseases. RAAS-blocking agents like angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers, have long
Chu-Lin Chou et al.
PloS one, 12(7), e0180712-e0180712 (2017-07-13)
Renin-angiotensin system in visceral fat plays a crucial role in the pathogenesis of metabolic syndrome in fructose-fed rats. However, the effects of renin inhibition on visceral adiposity in metabolic syndrome are not fully investigated. We investigated the effects of renin

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持